Study S000796

A 24 Week Monocentric Prospective Randomized, Placebo-controlled Trial to Evaluate Efficacy of Combination of Exenatide and Dapagliflozin Compared to Dapagliflozin and Placebo and Its Effects on Hepatic, Myocardial and Pancreatic Fat Distribution in Patients With Uncontrolled Type 2 Diabetes Mellitus.

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT03007329
Acronym: EXENDA
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: TRIPLE
Status: COMPLETED
Enrollment: 34
Start: 2017-03-08
Primary completion: 2019-11-26
Lead sponsor: Medical University of Vienna
Conditions: Steatosis, Liver; Type2 Diabetes
Interventions: DRUG:Exenatide; DRUG:Exenatide matching Placebo; DRUG:Dapagliflozin
Results posted: FALSE

Registered primary outcomes

change in hepatic lipid content measured with magnetic resonance spectroscopy in % [baseline - week 24]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0025594	Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial. Harreiter J, Diabetes, obesity & metabolism	2021	Randomized trial	PMID 33464703 DOI	registry reference RESULT:33464703